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Intravenous fluorouracil and leucovorin is the standard adjuvant treatment for stage III colon cancer. However, oral adjuvant
chemotherapy is attractive because it has low toxicity and greater convenience. We investigated the benefits of oral protein-bound
polysaccharide K (PSK) with tegafur/uracil (UFT) as an adjuvant in stage II and III colorectal cancer. Patients were assigned to groups
that received either 3g PSK plus 300mg UFT, or 300mg UFT alone orally each day for a 2-year period following intravenous
mitomycin C. Of 207 registered patients, 205 with stage II (n¼123) or III (n¼82) were analysed. The 5-year disease-free survival
was 73.0% (95% CI 65.6–80.4%) with PSK (n¼137) and 58.8% (95% CI 47.1–70.5%) in the controls (n¼68) (P¼0.016).
POLYSACCHARIDE K reduced the recurrence by 43.6% (95% CI 4.5–66.7%) and mortality by 40.2% (95% CI  12.5 to 68.3%). The
5-year survival was 81.8% (95% CI 75.3–88.2%) in the PSK group and 72.1% (95% CI 61.4–82.7%) in the control group (P¼0.056).
In stage III patients, disease-free and overall survivals in patients receiving PSK were increased significantly: 60.0% (95% CI 47.1–
72.9%) and 74.6% (95% CI 63.0–86.1%) in the PSK group as compared with 32.1% (95% CI 14.8–49.4%) and 46.4% (95% CI 28.0–
64.9%) in the controls (P¼0.002 and 0.003, respectively). Polysaccharide K prevented recurrence, particularly lung metastases
(P¼0.02; odds ratio 0.27; 95% CI 0.09–0.77). In the models, the presence of regional metastases (relative risk, 2.973; 95% CI 1.712–
5.165; Po0.001), omission of PSK (relative risk, 2.106; 95% CI 1.221–3.633; P¼0.007), and higher primary tumour (relative risk,
4.398; 95% CI 1.017–19.014; P¼0.047) were each significant indicators of recurrence. Adverse effects were mild and compliance
was good. Oral PSK with UFT reduced recurrence in stage II and III colorectal cancer, and increased survival in stage III.
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Currently, the standard adjuvant treatment for stage III colon
cancer is 5-fluorouracil plus leucovorin (5-FU/LV) for 6–8 months
(Francini et al, 1994; IMPACT, 1995; O’Connell et al, 1998). In an
attempt to improve the therapeutic index of 5-FU and its
tolerability, research has focused on the study of oral 5-FU
prodrugs. Tegafur/uracil (UFT
s; Taiho Pharmaceutical Co., Japan)
is an orally administered fluoropyrimidine inhibitor of dihydro-
pyrimidine dehydrogenase, and contains tegafur and uracil in a
1:4 molar ratio. Tegafur is an orally bioavailable prodrug of 5-FU,
and uracil reversibly inhibits the primary catabolic enzyme for 5-
FU, namely dihydropyrimidine dehydrogenase. Phase I/II studies
of advanced or metastatic colorectal cancer treated with different
regimens of UFT and LV achieved excellent response rates and had
favourable toxicity (Saltz et al, 1995; Feliu et al, 1997; Rustum,
1997). In phase III, oral UFT/LV provided a safer, more convenient
oral alternative to a standard bolus i.v. regimen of 5-FU/LV for
metastatic colorectal cancer, while producing equivalent survival
(Carmichael et al, 2002; Douillard et al, 2002).
PROTEIN-BOUND POLYSACCHARIDE K (KRESTIN
s; Kureha
Chemical Industry Co., Japan), extracted from the mycelia of
Coriolus versicolor, has immunomodulatory activities. It induces
the production of interleukin (IL)-2 and interferon (IFN) g, thereby
stimulating lymphokine-activated killer cells (LAK) and enhancing
natural killer (NK) cells (Hirose et al, 1990; Hayashida et al, 1991;
Ebina and Murata, 1992; Kato et al, 1995; Yefenof et al, 1995;
Algarra et al, 1997; Harada et al, 1997; Pedrinaci et al, 1999). We
have reported that adjuvant therapy with PSK increases the levels
of cytotoxic T cells, helper T cells, and NK cells in patients with
resected colorectal cancer (Ohwada et al, 1994).
PROTEIN-BOUND POLYSACCHARIDE K and UFT are popu-
larly used for adjuvant immunochemotherapy in gastric cancer
patients in Japan. In a few reports, PSK and UFT have been used as
adjuvant chemotherapy in colorectal cancer. A randomised,
double-blind trial of stage III and IV colorectal cancers using the
rules for colorectal cancer in Japan (this stage corresponds to
AJCC stage III) showed that PSK provided significant benefits in
improving disease-free and overall survival. The beneficial effects
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lof PSK have been attributed to the activation of leucocyte
chemotactic locomotion and phagocytic activity (Torisu et al,
1990). Adjuvant chemotherapy with PSK for over 3 years, and oral
5-FU for 2 years, following intravenous mitomycin C (MMC
s),
significantly increased the disease-free survival rate, as compared
with 5-FU alone in patients with curatively resected colorectal
cancer (Mitomi et al, 1992). These results were promising evidence
of survival benefits, and encouraged us to use oral PSK together
with UFT as an adjuvant immunochemotherapy.
To investigate the benefits of immunochemotherapy with oral
PSK plus UFT, we conducted a randomised, controlled trial
comparing PSK and UFT in combination, with UFT alone, for 2
years, in cases of curatively resected stage II and III colorectal
cancer. Here, we report the results of a 5-year follow-up.
PATIENTS AND METHODS
This study was carried out in the Gunma Oncology Study Group
(GOSG), which includes 19 affiliate hospitals of the Second
Department of Surgery, Gunma University Hospital, Maebashi,
Japan. Suitably qualified chief surgeons were trained in the Second
Department of Surgery, Gunma University Hospital, in order to
standardise surgical quality. Colon resection or tumour-specific
mesorectal excision (MacFarlane et al, 1993) with D2 or D3
lymphadenectomy was performed. Once a patient was registered,
his or her surgery and pathology reports, medical records, and
laboratory tests, including haematology and blood chemistry, were
reviewed by the quality-control committee of the GOSG. The ethics
committee of each institution approved the protocol, and written
informed consent was obtained directly from each patient before
registration.
Patients
All of the eligible patients had histologic confirmed colorectal
cancer, were less than 75 years old, had measurable serum
immunosuppressive acidic protein (IAP) levels, had a primary
tumour at stage II or III, and underwent macroscopically curative
resection. Patients were ineligible if they had undergone any
radiotherapy, chemotherapy, or immunotherapy, or had multiple
cancers, or severe complications. They were also ruled out if they
showed any of the following abnormal findings: white blood cell
count p4000mm
 3, platelet count p1 10
5mm
 3; total protein
level p6.0gdl
 1; serum alanine or aspartate aminotransferase
level X100IUl
 1; or creatinine level X1.5mgdl
 1. The subjects
were randomly allocated to two groups immediately after surgery,
using a centralised registration system. Assignment to the control
or PSK-treatment group was made by referring to a pre-set list
generated using a computer-assisted randomisation system.
Patients were allocated to PSK-treatment and control groups in
the ratio of 2:1, because PSK plus chemotherapy (MMC plus 5-FU)
had been shown to improve the disease-free and overall survival of
patients with curative resection of colorectal or gastric cancers
(Mitomi et al, 1992; Nakazato et al, 1994). The protocol called for a
total of 240 patients to be accrued over 3 years in an allocation
ratio of 2:1 of PSK-treated to control subjects (160 PSK and 80
control). This sample size would give an 80% probability of
detecting a 15% difference in 5-year disease-free survival, with a
two-sided a level of 0.05, which seemed both modest and
reasonable with respect to the previous study (Mitomi et al, 1992).
Study design
All registered patients received bolus injections of 12 and 8mgm
 2
MMC
s (Kyowa Hakko, Inc., Japan) on postoperative days 1 and 2,
respectively. The PSK group received oral PSK (3.0gday
 1) and
UFT (300mgday
 1), starting 2 weeks after surgery and continuing
for 2 years or until the diagnosis of tumour recurrence. The
controls received UFT monotherapy.
The patients were followed up every 2 weeks in the first month
after discharge, then once a month over the 2-year period of the
study, and finally once every 2 or 3 months until 5 years after
surgery. Patients were interviewed regarding drug intake on every
visit, and randomly selected patients were interviewed by
telephone. Drug diaries and pill counts were not used. Adverse
effects were recorded according to WHO criteria, and, if these
effects became intolerable, treatment was suspended until the
effects subsided. Patients underwent ultrasonography, computer-
aided tomography, and other procedures, as required, for every 6
months, to check for any evidence of cancer recurrence. When
recurrence was noted, patients received an optimal treatment
combination appropriate to their circumstances.
The disease-free and overall survival rates were the primary end
points, and causes of death and recurrence were also assessed.
Statistical analyses
Statistical analyses were carried out using the Statistical Analysis
System software (SAS, version 8.2,. Cary, NC, USA). An intention-
to-treat analysis was applied. Background factors were compared
using the w
2 or Mann–Whitney U-test. Disease-free and overall
survival curves were generated by the Kaplan–Meier method, and
the log-rank test was used to compare the curves. Deaths without
recurrence were censored. Proportional hazard regression analysis
was applied to estimate the percentage reduction in risk of
recurrence. Multivariate analyses using the Cox proportional-
hazards model were applied to estimate the simultaneous effects of
prognostic factors on survival. Variables were retained in the
model if the associated two-tailed P-values were 0.05 or less.
RESULTS
Patient characteristics
A total of 207 patients were enrolled in the trial between October
1994 and March 1997. Slightly fewer patients were enrolled than
the protocol sample called for, because the protocol study period
was adhered to. Of these, 139 patients were allocated to the PSK
group, and 68 to the control group. Two patients (1.4%) in the PSK
group were ineligible: one had macroscopic noncurative tumours,
and the other had multiple cancers. Consequently, 205 patients
were analysed (137 PSK and 68 controls). All the patients were
closely monitored throughout follow-up and no patients were lost
during that time. No patient received the relevant treatment for
more than 2 years. Table 1 lists the baseline characteristics and
histopathological classification of the subjects. There were no
striking differences between the groups with respect to stratifica-
tion factors or the histopathologic characteristics, including
pathologic staging, pathologic regional lymph nodes, lymphatic
invasion, venous invasion, and residual tumour excluding
histopathologic grade. The histopathologic grade was higher in
the PSK group than in the control group (P¼0.009).
Tumour recurrence and pattern of recurrence
In all, 57 patients had recurrences: 25 (36.5%; relative risk 0.66;
95% CI 0.45–0.98)) in the control group and 32 (23.3%; relative
risk 1.26; 95% CI 0.98–1.63) in the PSK group (P¼0.06; odds ratio
0.52; 95% CI 0.28–0.98). PROTEIN-BOUND POLYSACCHARIDE
K administration reduced the absolute recurrence by 57.5%. The
median time to recurrence was not significantly different
(P¼0.504) in the two groups: 2.071.4 years in the PSK group
and 1.671.1 years in the control group. The 6-month rate of
recurrence in the control group was higher in the first 2 years after
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lsurgery than later, whereas it was consistently low in the PSK
group over the 5 years following surgery (Figure 1).
Patients in the control group had 30 metastatic sites (relative
risk 0.62; 95% CI 0.42–0.90), while patients in the PSK group had
37 sites (relative risk 1.31; 95% CI 1.03–1.67) (P¼0.02; odds ratio
0.47; 95% CI 0.25–0.86). PROTEIN-BOUND POLYSACCHARIDE
K prevented recurrence, particularly lung metastases (P¼0.02;
odds ratio 0.27; 95% CI 0.09–0.77), although there were no
significant differences with regard to liver, peritoneal, local, and
lymph node metastases (Table 2).
Survival rates
The mean disease-free survival time of the PSK vs control group
was 50.3 months (95% confidence interval 47.2–53.4 months) vs
40.0 months (95% confidence interval 38.8–49.2 months)
(P¼0.031). The 5-year disease-free survival was 73.0% (95% CI
65.6–80.4%) with PSK and 58.8% (95% CI 47.1–70.5%) in the
controls (P¼0.016) (Figure 2). The estimated overall reduction in
the risk of recurrence with PSK therapy was 43.6% (95% CI 4.5–
66.7%). In pathologic stage III patients, the 5-year disease-free
survival benefit from PSK was significant: 60.0% (95% CI 47.1–
72.9%) in the PSK group as compared with 32.1% (95% CI 14.8–
49.4%) in the control group (P¼0.002) (Figure 3). The estimated
overall reduction in the risk of recurrence with PSK therapy in
pathologic stage III patients was 63.4% (95% CI 26.8–81.7%). No
disease-free survival benefit was apparent in a subgroup analysis of
colon and rectum, or pathologic stage II cancer.
All patients in whom there was recurrence received optimal
chemotherapy, trans-arterial chemotherapy, and salvage surgery.
Table 1 Patient baseline characteristics and macroscopic and histopathologic classification
Control group PSK group
Characteristic Category 68 100% 137 100% P-value Test
Age (years) 25–49 8 11.8% 14 10.2% 0.433 U
50–59 17 25.0% 33 24.1%
60–69 31 45.6% 57 41.6%
70–75 12 17.6% 33 24.1%
Sex Male 43 63.2% 71 51.8% 0.162 w
2
Female 25 36.8% 66 48.2%
IAP value 4500mgml
 1 21 30.9% 43 31.4% 1.000 w
2
p500mgml
 1 47 69.1% 94 68.6%
Location Colon 34 50.0% 88 64.2% 0.071 w
2
Rectum 34 50.0% 49 35.8%
Tumour size (cm)  3.9 16 23.5% 26 19.0% 0.356 U
4.0–5.9 30 44.1% 59 43.1%
6.0– 22 32.4% 52 38.0%
Residual tumour R0 68 100.0% 136 99.3% 1.000 w
2
R1 0 0.0% 1 0.7%
R2 0 0.0% 0 0.0%
Pathologic primary tumour T1 2 2.9% 4 2.9% 0.935 U
T2 9 13.2% 8 5.8%
T3 49 72.1% 120 87.6%
T4 8 11.8% 5 3.6%
Histolopathologic grade G0 36 52.9% 45 32.9% 0.009 w
2
G1 31 45.6% 81 59.1%
G2 1 1.5% 11 8.0%
Pathologic regional lymph nodes N0 40 58.8% 82 59.9% 0.555 U
N1 12 17.6% 35 25.5%
N2 16 23.5% 20 14.6%
Lymphatic invasion L0 24 35.3% 39 28.5% 0.403 w
2
L1 44 64.7% 98 71.5%
Venous invasion V0 34 50.0% 82 59.9% 0.190 U
V1 33 48.5% 53 38.7%
V2 1 1.5% 2 1.5%
Pathologic TNM stage* I 8 11.8% 11 8.0% 0.914 U
IIA 31 45.6% 68 49.6%
IIB 1 1.5% 3 2.2%
IIIA 3 4.4% 1 0.7%
IIIB 9 13.2% 34 24.8%
IIIC 16 23.5% 20 14.6%
IAP¼immunosuppressive acidic protein; *TNM cancer staging according to AJCC (6th edition).
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lIn total, 21 salvage operations were carried out, for hepatic
recurrence (10 patients), pulmonary metastasis (eight patients),
local recurrence (two patients), or lymph nodes (one patient). A
total of 21 patients (38.9%) remain alive: 12 (41.4%) patients in the
PSK group and nine (36.0%) in the control. Three patients in the
PSK group and two patients in the control group died from
nonrelated disease.
The mean survival time of the PSK group vs the control group
was 54.0 months (95% confidence interval 51.6–56.4 months) vs
50.8 months (95% confidence interval 46.6–54.9 months)
(P¼0.150). The 5-year overall survival was 81.8% (95% CI 75.3–
88.2%) in the PSK group and 72.1% (95% CI 61.4–82.7%) in the
control group (P¼0.056) (Figure 4). The estimated overall
reduction in mortality with PSK therapy was 40.2% (95% CI
 12.5 to 68.3%). In pathologic stage III patients, the 5-year overall
survival benefit from PSK was significant: 74.6% (95% CI 63.0–
86.1%) in the PSK group, as compared with 46.4% (95% CI 28.0–
64.9%) in the control group (P¼0.003) (Figure 5). The estimated
overall reduction in mortality with PSK therapy in pathologic stage
III patients was 66.2% (95% CI 24.8–84.8%). No selective survival
benefit with PSK was apparent in a subgroup analysis of colon and
rectum, or pathologic stage II cancer.
Relative risks of recurrence according to proportional-
hazards regression models
We analysed proportional-hazards regression models adjusted for
sex, age, serum IAP levels, tumour locations, tumour size,
pathologic primary tumour, presence or absence of regional
metastases, and pathologic staging. It was found that lymphatic
invasion, venous invasion, administration of PSK, pathologic
primary tumour, and the presence or absence of regional
metastases were each independently associated with an increased
risk of recurrence. In the models, the presence of regional
16
14
12
10
8
6
2
0
4
Years after surgery
H
a
z
a
r
d
 
r
a
t
e
 
(
%
)
Group C
Group P
012345
Figure 1 Recurrence hazard rate per 6-month interval.
Table 2 Tumour recurrence and pattern of recurrence
Control group PSK group
N¼68 RR 95% CI N¼137 RR 95% CI OR 95% CI P-value
No of patients with recurrence
sites
25 (36.5%) 0.66 0.45–0.98 32 (23.3%) 1.26 0.98–1.63 0.52 0.28–0.98 0.06
Distant metastasis 21 0.67 0.45–0.99 26 1.27 0.96–1.67 0.52 0.27–1.02 0.08
Lung 10 0.49 0.32–0.76 6 1.85 0.97–3.50 0.27 0.09–0.77 0.02
Liver 9 1.04 0.58–1.85 19 0.98 0.75–1.29 1.06 0.45–2.48 1.00
Bone 1 0.33 0.27–0.40 0 0.72
Brain 1 0.33 0.27–0.40 0 0.72
Miscellaneous 0 1 0.67 0.61–0.73 1.00
Peritoneum 4 0.91 0.40–2.03 7 1.05 0.67–1.66 0.86 0.24–3.05 1.00
Lymph node 3 0.43 0.24–0.79 1 2.71 0.49–14.82 0.16 0.02–1.56 0.21
Local 2 0.83 0.28–2.46 3 1.12 0.54–2.30 0.74 0.12–4.53 1.00
Total 30 0.62 0.42–0.90 37 1.31 1.03–1.67 0.47 0.25–0.86 0.02
RR¼relative risk, OR¼odds ratio.
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Figure 2 Disease-free survival (5-year) in all patients.
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Figure 3 Disease-free survival (5-year) of patients with pathologic stage
III cancer.
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lmetastases (relative risk 2.973; 95% CI 1.712–5.165; Po0.001),
omission of PSK (relative risk 2.109; 95% CI 1.221–3.633;
P¼0.007), and higher pathologic grade of primary tumour
(relative risk 4.398; 95% CI 1.017–19.014; P¼0.047) were each
significant indicators for recurrence (Table 3).
Treatment compliance
In all, 89% of all patients were fully drug compliant: 87.6% in the
PSK group and 91.2% in the control group. A total of 13 patients
(6.3%) – nine (6.6%) in the PSK group and four (5.9%) in the
control group – temporarily stopped taking the drugs because of
adverse effects: gastrointestinal toxicity in five patients, myelo-
suppression in three patients, hepatotoxicity in two patients,
dermatitis in two patients, and neurotoxicity in one patient.
Another cause was bowel obstruction. Five patients refused
treatment: four (2.9%) in the PSK group and one (1.5%) in the
control group. Three patients received no treatment of MMC: two
(1.5%) in the PSK group and one (1.5%) in the control group.
Compliance with UFT and PSK was good, as confirmed by
interviews and measurements of the urinary tegafur concentration
carried out on 24 randomly selected patients between 11 and 24
months after surgery.
Adverse effects
A total of 31 patients (15.1%) had grade 1 or 2 haematological or
gastrointestinal toxicity. No grade 3 or 4 toxicity was observed.
Gastrointestinal toxicity, such as loss of appetite, nausea, vomiting,
diarrhoea, and stomatitis, was seen in 12 patients (5.8%). Other
forms of toxicity included: haematological, 10 patients (4.9%);
hepatotoxic, five patients (2.4%); neurotoxic, three patients, and
dermatological, two patients. Toxicity occurred within 3 months
after surgery, and was induced by the MMC and subsequent UFT
treatments. MMC was definitively responsible for haematological
toxicity in seven out of the 10 patients, because it occurred within
2 weeks of surgery.
Second primary cancers
A total of 11 patients (5.4%) had second primary cancers: four
(5.9%) in the control group and seven (5.1%) in the PSK group.
Colorectal cancer occurred in five patients, while breast, lung,
ovary, gall bladder, and pancreatic cancer occurred in one patient
each. Curative-intent resections were performed on all patients,
eight of whom have survived disease-free. One patient died from
pancreatic cancer and another two died from the primary cancer.
DISCUSSION
The study showed that oral PSK plus UFT reduced the risk of
recurrence by 43.6% in patients with stage II or III, and reduced
the overall death rate in patients with pathologic stage III
colorectal cancer. In Cox proportional hazard models, the
administration of PSK decreased the risk of recurrence and that
of lymph node metastasis and a lower primary tumour.
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Figure 4 Overall survival (5-year) in all patients.
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Figure 5 Overall survival (5-year) of patients with pathologic stage III
cancer.
Table 3 Relative risks of recurrence according to proportional-hazards
regression models
Characteristic Category Harard ratio 95% CI P-value
Sex Male
Female 0.976 0.586–1.624 0.924
Age (years) 60–
–59 1.295 0.774–2.168 0.325
IAP value 4500mgml
 1
X500mgml
 1 1.357 0.777–2.370 0.284
Location Colon
Rectum 1.446 0.866–2.483 0.154
Tumour size (cm)  3.9
4.0–5.9 1.029 0.514–2.061 0.935
6.0– 1.119 0.551–2.274 0.755
Primary tumour T1, 2
T3, 4 4.398 1.017–19.014 0.047
Histopathologic grade G0
G1, 2 1.380 0.764–2.496 0.286
Regional lymph nodes N0
N1, 2, 3 2.973 1.712–5.165 o0.001
Lymphatic invasion L0
L1 1.089 0.520–2.283 0.821
Venous invasion V0
V1, 2 1.127 0.637–1.993 0.681
Group PSK
Control 2.109 1.221–3.633 0.007
IAP¼immunosuppressive acidic protein.
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UFT monotherapy and 23.3% with UFT/PSK, with the majority of
recurrences being distant metastasis. PROTEIN-BOUND POLY-
SACCHARIDE K achieved a 57.5% absolute reduction in
recurrence at the 5-year follow-up. The recurrence rate was
34.9–37% for stages II and III, and 33.5–39.3% for stage III with 5-
FU/LV and 5-FU/levamisole treatment (QUASAR, 2000; Porschen
et al, 2001), whereas the rates were 49–60% without adjuvant
chemotherapy. PROTEIN-BOUND POLYSACCHARIDE K reduced
the risk of recurrence by 43.6% in stages II and III, and by 63.4% in
pathologic stage III, which is equivalent to the reported 33.5–41%
with 5-FU/levamisole or 5-FU/LV (Moertel et al, 1990; Francini
et al, 1994; IMPACT, 1995).
In curative resected stage III colon cancer, the 4-year survival
estimates range from 46 to 57% (Moertel et al, 1990; Francini et al,
1994; IMPACT, 1995). Adjuvant therapy with 5-FU/levamisole
increased postoperative survival to 71% at 31
2 years (Moertel et al,
1990). Further, adjuvant treatment with 5-FU modulated by LV
increased 4-year survival to over 71–72% (Francini et al, 1994;
IMPACT, 1995; QUASAR, 2000; Porschen et al, 2001). In our stage
III patients, the 4-year disease-free and overall survival rates were
69.1 and 78.2% in the PSK group, as compared with 35.7 and 50%
in the controls, respectively. The 5-year disease-free and overall
survival rates were 60.0 and 74.6% in the PSK group, as compared
with 32.1 and 46.4% in the controls, respectively. A randomised,
double-blind study showed that the 5-year disease-free survival for
PSK vs placebo was 38 vs 20%, and overall survival for PSK vs
placebo was 50 vs 40%, respectively (Torisu et al, 1990). Survival
with PSK/UFT treatment in pathologic stage III patients was
comparable or superior to standard regimens of 5-FU/LV or 5-FU/
levamisole (Moertel et al, 1990; Francini et al, 1994; IMPACT,
1995). However, survival with UFT monotherapy in pathologic
stage III patients was worse, and was similar to that of untreated
controls in standard regimen studies (Moertel et al, 1990; Francini
et al, 1994; IMPACT, 1995). It is difficult to explain why survival in
stage III was poor with UFT monotherapy; it might be explained by
the difference in dose intensity of UFT. Tegafur/uracil was
administered at a dosage of 600mgbody
 1 in three divided doses
daily (Malik et al, 1990) or 300 or 350mgm
 2day
 1 with LV (Saltz
et al, 1995) in metastatic colorectal cancer. Our dose of UFT was
less than that in those studies, despite the absence of LV
modulation. There was a dose-dependent reduction in the odds
of death for patients receiving 5-FU regimens (Zalcberg et al,
1996), while the dosage intensity was not a factor in the survival
benefits (Higgins et al, 1976; Grage and Moss, 1981). Therefore, it
remains speculative whether the poorer survival is explained by
the difference in the dose intensity of UFT.
Studies may have shown a better tendency in overall survival,
simply because the survival of pathologic stage II patients is so
much better even without treatment. Another reason may be that
the second-line treatments for recurrence, including chemotherapy
and salvage surgical therapy, prolong the survival of these patients
(Okumura et al, 1996; Goldberg et al, 1998; Saltz et al, 2000; Choti
et al, 2002). All patients with recurrence received chemotherapy,
trans-arterial chemotherapy, and salvage surgery (Tomizawa et al,
in press). These treatments for recurrence certainly prolong overall
survival and, in this era of active treatment, strategies for
recurrence of disease-free survival may be more meaningful than
overall survival, at least in the case of adjuvant chemotherapy for
colorectal cancer.
The benefits of fluorouracil-based therapy for pathologic stage II
colon cancer are unclear. While adjuvant active specific immu-
notherapy with BCG vaccine significantly lowered tumour
recurrence in stage II colon cancer (Vermorken et al, 1999), we
detected no beneficial effects of UFT/PSK with regard to the overall
or disease-free survival rates in pathologic stage II cancer in this
study, nor was it observed previously (Moertel et al, 1990; Mitomi
et al, 1992). However, 20% of patients with pathologic stage II
cancers die of recurrent disease, and lymph node micro-metastases
are detected by molecular analysis in 54% of patients (Liefers et al,
1998). Molecular-based analyses would facilitate the selective use
of adjuvant therapy and prevent unnecessary treatments.
Immunosuppressive acidic protein, isolated from the ascitic
fluids of cancer patients, suppresses both phytohemagglutinin-
induced lymphocyte blast formation and the mixed-lymphocyte
reaction in vitro (Tamura et al, 1981). We expected the pre-
operative IAP value to be a good predictor of PSK response,
because a serum IAP value above 580mgml
 1, determined as an
appropriate threshold value using Cox’s proportional hazards
model, has been reported to be a good indicator of enhanced
survival in gastric cancer patients (Nakazato et al, 1994; Sakamoto
et al, 1996). In Cox proportional-hazards regression models, the
presence of regional metastases, omission of PSK, and higher
primary tumour were each significant indicators of recurrence.
Nevertheless, in this study, the pre-operative serum IAP level was
not a significant predictor of survival.
The duration of adjuvant chemotherapy after colorectal cancer
varies (Moertel et al, 1990; O’Connell et al, 1998; QUASAR, 2000;
Porschen et al, 2001), and there is no consensus on the optimal
duration of adjuvant chemotherapy. Currently, the standard
adjuvant treatment for stage III colon cancer is 5-FU/LV for 6–8
months (Francini et al, 1994; IMPACT, 1995; O’Connell et al,
1998). When our study was designed, the optimal treatment
duration was thought to be 2 years, because the risk of recurrence
is greatest during that period and randomised controlled studies in
which PSK and chemotherapy were administered for 18, 24, and
over 36 months, showed a significant reduction in recurrence
(Torisu et al, 1990; Mitomi et al, 1992; Nakazato et al, 1994, 1999).
Indeed, in our study, 71% of cancers recurred during the first 2
years after surgery, and 85% recurred within 2 years and 6 months
after surgery. The oral use of adjuvant chemotherapy with PSK and
UFT has low toxicity, is simple, and does not require frequent
treatment-related visits, thereby helping to ensure that patients
receive treatment for 2 years.
Experimental studies have shown that PSK suppresses micro-
metastases of the liver by enhancing the activities of NK cells and
macrophages (Morinaga et al, 1994). It also reduces tumour cell
invasiveness by downregulating several invasion-related factors,
including TGF-b1, urokinase plasminogen activator (uPA), and
matrix metalloproteinases (MMPs)-2 and -9, which are produced
by tumour cells (Zhang et al, 2000). PROTEIN-BOUND POLY-
SACCHARIDE K restores host immune functions that are
suppressed by tumour or antitumour chemotherapeutic agents,
thereby producing IL-2 and IFN g, and stimulating the activities of
LAK and NK cells. PROTEIN-BOUND POLYSACCHARIDE K
induces IL-1, IL-6, and IL-8 in peripheral mononuclear cells, as
well as tumour necrosis factor and macrophage chemotactic factor
at the tumour sites (Hirose et al, 1990; Ebina and Murata, 1992),
thereby activating programmed cell death (Yefenof et al, 1995;
Lacour et al, 2001). Therefore, the increased disease-free survival
rates and marked reduction in lung metastases seen in this study
may be evidence of immunological and biochemical modulation by
PSK.
The toxicity of adjuvant chemotherapy regimens needs to be
considered in selecting the optimal therapy. Oral PSK and UFT
have less frequent and lower grade toxicity than 5-FU/levamisole
and 5-FU/LV (Moertel et al, 1990; IMPACT, 1995; O’Connell et al,
1998; QUASAR, 2000; Porschen et al, 2001). Only 6.3% of the
patients in this study discontinued treatment because of adverse
drug effects. Of our patients, 15.4% showed grade 1 or 2
haematological and gastrointestinal toxic effects, while none had
grade 3 or 4 effects. Drug compliance was better and was
confirmed by interviews and measurements of the urinary tegafur
concentration, as compared with well-tolerated standard regimens
(Moertel et al, 1990; IMPACT, 1995; O’Connell et al, 1998;
QUASAR, 2000; Porschen et al, 2001).
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number of patients were enrolled, and the control arm did not
consist of the standard adjuvant therapy with 5-FU/LV. Never-
theless, the results seem sufficiently promising to justify a larger
scale study of adjuvant chemotherapy using oral PSK and UFT as
an alternative to intravenous 5-FU/LV as the standard comparator
arm. Future investigations will seek to progress beyond the era of
5-FU/LV.
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